Camptothecin derivative-loaded poly(caprolactone-co-lactide)-b-PEG-b-poly(caprolactone-co-lactide) nanoparticles and their biodistribution in mice.

Triblock copolymers of poly(caprolactone-co-lactide)-b-PEG-b-poly(caprolactone-co-lactide) (PCLLA-PEG-PCLLA) were synthesized by ring opening copolymerization of caprolactone and lactide in the presence of poly(ethylene glycol) (PEG). With such triblock copolymers, PCLLA-PEG-PCLLA nanoparticles entrapping 10-hydroxycamptothecin-10,20-diisobutyl dicarbonate (HCPT-1), a derivative of the antitumor drug 10-hydroxycamptothecin (HCPT), were prepared by nano-precipitation method and characterized by dynamic light scattering (DLS), transmission electron microscopy (TEM) and atomic force microscopy (AFM). The investigations on drug loading, in vitro release and body distribution in mice after intravenous (i.v.) administration were also carried out. It is found that the obtained nanoparticles showed smooth surface and spherical shape with the controllable size in the range of 70-180 nm, and drug loading content varied from 3.3% to 7.0% depending on the copolymer composition and preparation conditions. The in vitro release behavior exhibited a sustaining release manner and was affected by particle size as well as copolymer composition. The results of body distribution study in mice show that the blood concentration of HCPT-1 could be maintained for a long period and the tissue distribution was influenced by the particle size to some extent. These results suggest that the PCLLA-PEG-PCLLA nanoparticles seem to be a promising delivery system for poorly soluble antitumor drugs or their derivatives.

[1]  T. Okano,et al.  Characterization of physical entrapment and chemical conjugation of adriamycin in polymeric micelles and their design for in vivo delivery to a solid tumor. , 1998, Journal of controlled release : official journal of the Controlled Release Society.

[2]  K. Kohn,et al.  Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: evidence for a specific receptor site and a relation to antitumor activity. , 1989, Cancer research.

[3]  Y. Nagasaki,et al.  Preparation and characterization of polymer micelles from poly(ethylene glycol)-poly(D,L-lactide) block copolymers as potential drug carrier. , 1999, Journal of controlled release : official journal of the Controlled Release Society.

[4]  M. Wirth,et al.  Poly(D,L-lactic-co-glycolic acid) microspheres for sustained delivery and stabilization of camptothecin. , 1999, Journal of controlled release : official journal of the Controlled Release Society.

[5]  Jiangning Chen,et al.  Preparation and drug release behaviors of nimodipine-loaded poly(caprolactone)-poly(ethylene oxide)-polylactide amphiphilic copolymer nanoparticles. , 2003, Biomaterials.

[6]  H. Maeda,et al.  Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[7]  R. Müller,et al.  'Stealth' corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption. , 2000, Colloids and surfaces. B, Biointerfaces.

[8]  J. O’Leary,et al.  Camptothecins: a review of their development and schedules of administration. , 1998, European journal of cancer.

[9]  Haixiong Ge,et al.  Preparation, characterization, and drug release behaviors of drug‐loaded ε‐caprolactone/L‐lactide copolymer nanoparticles , 2000 .

[10]  S M Moghimi,et al.  Long-circulating and target-specific nanoparticles: theory to practice. , 2001, Pharmacological reviews.

[11]  B. Giovanella,et al.  Alkyl esters of camptothecin and 9-nitrocamptothecin: synthesis, in vitro pharmacokinetics, toxicity, and antitumor activity. , 1998, Journal of medicinal chemistry.

[12]  Y. Cai,et al.  Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain. , 1999, Journal of controlled release : official journal of the Controlled Release Society.

[13]  A. McPhail,et al.  Plant Antitumor Agents. I. The Isolation and Structure of Camptothecin, a Novel Alkaloidal Leukemia and Tumor Inhibitor from Camptotheca acuminata1,2 , 1966 .

[14]  H. Zhao,et al.  20-O-acylcamptothecin derivatives: evidence for lactone stabilization. , 2000, The Journal of organic chemistry.

[15]  Teruo Okano,et al.  Polymeric micelles as new drug carriers , 1996 .

[16]  Y. M. Lee,et al.  Taxol-loaded block copolymer nanospheres composed of methoxy poly(ethylene glycol) and poly(epsilon-caprolactone) as novel anticancer drug carriers. , 2001, Biomaterials.

[17]  M. Rothenberg.  Topoisomerase I inhibitors: review and update. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  Teruo Okano,et al.  Enhanced tumor accumulation and prolonged circulation times of micelle-forming poly(ethylene oxide-aspartate) block copolymer-Adriamycin conjugates , 1994 .

[19]  Shen‐guo Wang,et al.  Morphology and biodegradation of microspheres of polyester–polyether block copolymer based on polycaprolactone/polylactide/poly(ethylene oxide) , 2000 .

[20]  D. Maysinger,et al.  Micellar Nanocontainers Distribute to Defined Cytoplasmic Organelles , 2003, Science.

[21]  T. Burke,et al.  Stabilization of 10-Hydroxycamptothecin in Poly(lactide-co-glycolide) Microsphere Delivery Vehicles , 1997, Pharmaceutical Research.

[22]  R. Gref,et al.  MPEO-PLA nanoparticles: effect of MPEO content on some of their surface properties. , 1999, Journal of biomedical materials research.

[23]  V. Torchilin,et al.  Biodegradable long-circulating polymeric nanospheres. , 1994, Science.

[24]  B. Amsden,et al.  Camptothecin Delivery Methods , 2002, Pharmaceutical Research.

[25]  Shen‐guo Wang,et al.  Self-Assembly of Poly(caprolactone-b-ethylene oxide-b-caprolactone) via a Microphase Inversion in Water , 2001 .

[26]  A. Eisenberg,et al.  Incorporation and Release of Hydrophobic Probes in Biocompatible Polycaprolactone-block-poly(ethylene oxide) Micelles: Implications for Drug Delivery , 2002 .

[27]  Christine Allen,et al.  Nano-engineering block copolymer aggregates for drug delivery , 1999 .

[28]  P. Couvreur,et al.  Long-Circulating PEGylated Polycyanoacrylate Nanoparticles as New Drug Carrier for Brain Delivery , 2001, Pharmaceutical Research.

[29]  Martin C. Garnett,et al.  Physicochemical Evaluation of Nanoparticles Assembled from Poly(lactic acid)−Poly(ethylene glycol) (PLA−PEG) Block Copolymers as Drug Delivery Vehicles , 2001 .